- 大部份公司都有淡旺季, 所以通常是看年增率
- 如果是成長期(在炒新的成長動能)的公司或景氣從谷底翻揚, 就可以觀察月增率
- 漲很多的股票要留意營收年增率或月增率大幅減少, 又或者是合約負債已經開始減少
- 留意短期平均營收向上或向下穿越長期平均營收
- 觀察累計營收年增率的累計增加或虧損收斂
| 年/月 | 營收 | 月增率(%) | 去年同期年增率(%) | 累計營收 | 累計營收年增率(%) | 近三月累計營收 | 存貨銷售比 | 自結稅前EPS | 自結稅前累計EPS | 備註(年增率變動50%需說明原因) |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024/10 | 1.13 | 175.35 | 0.0 | 1.63 | -48.12 | 1.54 | N/A | 本月營收較去年同期增加，係因本月認列授權簽約金收入；本年累計較去年同期減少，係因前期認列授權簽約金收入較高所致。 | ||
| 2024/9 | 0.41 | 0.0 | 0.0 | 0.51 | -83.93 | 0.41 | 0.46 | 本月營收較去年同期增加，係因本月認列銷貨收入；本年累計較去年同期減少，係因前期認列授權簽約金收入。 | ||
| 2024/8 | 0.0 | 0.0 | 0.0 | 0.1 | -96.94 | 0.0 | 0 | 去年係因認列授權簽約金收入。 | ||
| 2024/7 | 0.0 | 0.0 | -100.0 | 0.1 | -96.94 | 0.1 | 1.99 | 去年同期係因認列授權簽約金收入。 | ||
| 2024/6 | 0.0 | -100.0 | 0.0 | 0.1 | 0.0 | 0.1 | 3.77 | 銷售L606研發用藥及保健食品 | ||
| 2024/5 | 0.1 | 0.0 | 0.0 | 0.1 | 0.0 | 0.1 | 3.77 | 銷售L606研發用藥 | ||
| 2024/4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | N/A | 銷售保健食品之營收 | ||
| 2024/3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | N/A | 銷售保健食品之營收 | ||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A |
- 每季的合約負債通常會反應在未來半年到一年後的營收
| 合約負債 QoQ YoY | |||
|---|---|---|---|
| 24Q3 (20) | 0.07 | -75.86 | 0 |
| 24Q2 (19) | 0.29 | 0.0 | 0 |
| 24Q1 (18) | 0.29 | 0 | 0 |
